Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
BCR-ABL TKI
Imatinib
Gleevec · IMA
The pioneering BCR-ABL TKI, with fluid retention, a slow eGFR drift, and uncommon proximal tubular (Fanconi-type) injury.
MildBCR-ABL tyrosine kinase inhibitor · approved 2001
Chronic myeloid leukemiaPhiladelphia-positive acute lymphoblastic leukemiaGastrointestinal stromal tumor
Signature kidney injury
Electrolyte Wasting
Periorbital/peripheral edema and fluid retention are common. Clinically meaningful renal injury is uncommon: long-term front-line imatinib is associated with a modest, measurable decline in eGFR over years, while proximal tubular dysfunction (hypophosphatemia, aminoaciduria, rare Fanconi syndrome) and AKI (including rare urate nephropathy from disease cytoreduction) are described at the case level.
Source: Molica et al., Ann Hematol 2018 (front-line TKI eGFR cohort)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
Incidence not quantified
SeverityMild
ReversibilityReversible
Evidence0 refs
Nephron map
Proximal Tubule
Distal Tubule / Collecting DuctFine-tuning of Na, K, Mg, acid & water
Electrolyte Wasting
Renal loss of magnesium, potassium or calcium — cisplatin and the anti-EGFR antibodies.
Mechanism of kidney injury
Proximal tubular injury is the main renal-specific mechanism: experimental and clinical data implicate mitochondrial impairment and oxidative stress in proximal tubular cells, manifesting as phosphate wasting, aminoaciduria, low-molecular-weight proteinuria, and occasionally a full Fanconi pattern. Off-target inhibition of PDGFR and c-KIT contributes to fluid retention and to the slow eGFR change. Rare AKI can be prerenal/obstructive from urate nephropathy when bulky disease is rapidly debulked.
Clinical presentation
Edema and weight gain; hypophosphatemia and hypokalemia; normoglycemic glucosuria, aminoaciduria, and LMW proteinuria in Fanconi-type cases; gradual creatinine rise and eGFR decline over years; rarely anuric AKI with urate crystals.
Onset
Edema early; tubular dysfunction and eGFR decline develop over months to years.
Reversibility
Reversible
Anticancer mechanism
First-generation tyrosine kinase inhibitor that occupies the ATP-binding pocket of BCR-ABL1 (and c-KIT and PDGFR), blocking constitutive kinase signaling that drives leukemic and stromal-tumor proliferation. Used in chronic myeloid leukemia, Ph+ ALL, and GIST.
Management
Replete phosphate/electrolytes and give supportive care for edema; reduce or interrupt the dose for significant AKI or tubular dysfunction. Tubular abnormalities and eGFR decline are generally mild and often improve with dose modification. Treat urate nephropathy with hydration and rasburicase.
Risk factors
- Prolonged therapy
- Older age and lower baseline eGFR
- Pre-existing renal impairment
- Concurrent nephrotoxins; high tumor burden (urate risk)
Prevention
- Monitor creatinine, eGFR, phosphate, and electrolytes during long-term therapy
- Phosphate and electrolyte repletion as needed
- Manage edema with dose adjustment and supportive care; TLS precautions in bulky disease
Note · Fanconi syndrome and AKI are rare and case-level; the everyday issues are fluid retention, hypophosphatemia, and a slow eGFR decline on long-term therapy.
Clinical depth
Renal dose adjustment
Reduce the starting dose by ~50% for severe renal impairment (CrCl <20 mL/min) and use caution with moderate impairment; standard starting doses are otherwise unchanged. Adjust for tolerability rather than by a strict eGFR algorithm.
Dialyzability & ESKD dosing
Imatinib is highly protein-bound (~95%) with a large volume of distribution and is not appreciably removed by hemodialysis; supplemental post-dialysis dosing is not required.
Differential diagnosis
Distinguish the slow imatinib eGFR drift and Fanconi pattern from prerenal azotemia (edema can coexist with intravascular depletion), from other causes of hypophosphatemia, and from disease-related urate nephropathy. A proximal tubular signature (glucosuria with normoglycemia, phosphaturia, aminoaciduria) is the tell for direct tubular toxicity.
Monitoring
- Serum creatinine/eGFR at baseline and periodically on long-term therapy
- Serum phosphate and electrolytes
- Weight/edema assessment at visits
- Urinalysis for glucosuria/proteinuria if tubular dysfunction suspected
Key trials & series
- IRIS (long-term front-line imatinib outcomes in CML)
- Molica et al. front-line TKI eGFR cohort (Ann Hematol 2018)
Clinical pearls
- Everyday imatinib renal issues are fluid retention, hypophosphatemia, and a gradual eGFR decline - not dramatic AKI.
- Think Fanconi when you see normoglycemic glucosuria plus phosphate wasting on imatinib.
- Imatinib is not dialyzed - no supplemental dosing needed in ESKD.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Electrolyte WastingFanconi SyndromeAcute Tubular Necrosis
Beyond the kidney
Class-level context for the major non-renal toxicities of bcr-abl tkis.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Vascular occlusion (ponatinib), fluid retention
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Pleural effusions (dasatinib), PAH
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- QT, heart failure
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkImatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.Ianotto JC et al. · Am J Hematol 2012 · PMID 22287505Clinical demonstration of imatinib-induced proximal tubular (Fanconi-type) aminoaciduria.PMIDThe potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury.Emadi E et al. · Heliyon 2019 · PMID 31294126Mechanistic study linking imatinib tubular injury to mitochondrial dysfunction and oxidative stress.PMIDChanges in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.Molica M et al. · Ann Hematol 2018 · PMID 29806063Front-line imatinib associated with a measurable decline in eGFR over time.PMIDLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.Hochhaus A et al. · N Engl J Med 2017 · PMID 28273028IRIS 10-year follow-up establishing long-term imatinib efficacy/safety, the backbone for chronic-exposure renal observations.PMIDAnuric Acute Kidney Injury in Chronic Myeloid Leukemia: A Rare Complication Case.Tjahjadi AK et al. · Acta Med Indones 2024 · PMID 39865048Illustrates rare urate-nephropathy AKI in an imatinib-treated CML patient, managed with hydration, hypouricemics, and dialysis.PMIDNew drug toxicities in the onco-nephrology world.Perazella MA et al. · Kidney Int 2015 · PMID 25671763Onco-nephrology review of TKI and other targeted-agent renal effects.